Literature DB >> 29890158

Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes.

Branka Djordjevic1, Tatjana Cvetkovic2, Tatjana Jevtovic Stoimenov2, Milena Despotovic2, Slavoljub Zivanovic3, Jelena Basic2, Andrej Veljkovic2, Aleksandra Velickov4, Gordana Kocic2, Dusica Pavlovic2, Dusan Sokolovic2.   

Abstract

Hyperglycemia mediated oxidative stress and pro-angiogenic molecules such as vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP9) are considered important for diabetic retinopathy onset and progression. Melatonin is a pineal hormone that regulates circadian and seasonal rhythms and most likely is involved in regulating glucose metabolism. We aimed to evaluate the potential benefit of melatonin supplementation to the pre-diabetic retina by assessing melatonin effects on lipid peroxidation (thiobarbituric acid reactive substances, TBARS), protein oxidation (advanced oxidation protein products, AOPP) and concentrations of inducible nitric oxide synthase (iNOS), VEGF and MMP9 in the retina of rats with pre-diabetes. Pre-diabetes was induced by streptozotocin (45 mg/kg, i.p.) following nicotinamide injection (110 mg/kg, i.p.). Beside mild hyperglycemia, lower serum insulin, increased fructosamine and lower HDL cholesterol, the present study demonstrated decreased serum melatonin in pre-diabetic rats, as well as, increased concentration of retinal TBARS, AOPP, iNOS, VEGF, and MMP9. Oral supplementation with melatonin (85 μg/animal/day) caused melatonin and HDL cholesterol levels to rise in treated rats and reduced levels of fasting serum glucose and fructosamine. It also affected serum insulin and quantitative insulin sensitivity check index (QUICKI) in treated groups but had no significant effect on non-fasting glucose. Finally, supplementation with melatonin reduced concentrations of TBARS, AOPP, iNOS, VEGF, and MMP9 in significant level, thereby exerting an overall positive effect on oxidative stress and pro-angiogenic signaling in the pre-diabetic retina. Thus, oral melatonin might be considered in an early treatment or in the prevention of retinal changes associated with pre-diabetes.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetic retinopathy; MMP9; Melatonin; Oxidative stress; Pre-diabetes; VEGF

Mesh:

Substances:

Year:  2018        PMID: 29890158     DOI: 10.1016/j.ejphar.2018.06.011

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review.

Authors:  Mohsen Imenshahidi; Golamreza Karimi; Hossein Hosseinzadeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-30       Impact factor: 3.000

Review 2.  Inherited Retinal Dystrophies: Role of Oxidative Stress and Inflammation in Their Physiopathology and Therapeutic Implications.

Authors:  Isabel Pinilla; Victoria Maneu; Laura Campello; Laura Fernández-Sánchez; Natalia Martínez-Gil; Oksana Kutsyr; Xavier Sánchez-Sáez; Carla Sánchez-Castillo; Pedro Lax; Nicolás Cuenca
Journal:  Antioxidants (Basel)       Date:  2022-05-30

Review 3.  The Role of Metalloproteinases and Their Tissue Inhibitors on Ocular Diseases: Focusing on Potential Mechanisms.

Authors:  Miłosz Caban; Katarzyna Owczarek; Urszula Lewandowska
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

Review 4.  Therapeutic potential of melatonin as a chronobiotic and cytoprotective agent in diabetes mellitus.

Authors:  Fareha Wajid; Raju Poolacherla; Fatiha Kabir Mim; Amna Bangash; Ian H Rutkofsky
Journal:  J Diabetes Metab Disord       Date:  2020-07-21

Review 5.  Circadian rhythms in diabetic retinopathy: an overview of pathogenesis and investigational drugs.

Authors:  Ashay D Bhatwadekar; Varun Rameswara
Journal:  Expert Opin Investig Drugs       Date:  2020-12-02       Impact factor: 6.206

Review 6.  Update on the Effects of Antioxidants on Diabetic Retinopathy: In Vitro Experiments, Animal Studies and Clinical Trials.

Authors:  Jose Javier Garcia-Medina; Elena Rubio-Velazquez; Elisa Foulquie-Moreno; Ricardo P Casaroli-Marano; Maria Dolores Pinazo-Duran; Vicente Zanon-Moreno; Monica Del-Rio-Vellosillo
Journal:  Antioxidants (Basel)       Date:  2020-06-26

Review 7.  Adjuvant Therapies in Diabetic Retinopathy as an Early Approach to Delay Its Progression: The Importance of Oxidative Stress and Inflammation.

Authors:  Ricardo Raúl Robles-Rivera; José Alberto Castellanos-González; Cecilia Olvera-Montaño; Raúl Alonso Flores-Martin; Ana Karen López-Contreras; Diana Esperanza Arevalo-Simental; Ernesto Germán Cardona-Muñoz; Luis Miguel Roman-Pintos; Adolfo Daniel Rodríguez-Carrizalez
Journal:  Oxid Med Cell Longev       Date:  2020-03-11       Impact factor: 6.543

Review 8.  Potential Role of Melatonin as an Adjuvant for Atherosclerotic Carotid Arterial Stenosis.

Authors:  Rui Zhang; Leng Ni; Xiao Di; Baitao Ma; Shuai Niu; Zhihua Rong; Changwei Liu
Journal:  Molecules       Date:  2021-02-04       Impact factor: 4.411

Review 9.  Effects of Melatonin on Diabetic Neuropathy and Retinopathy.

Authors:  Klausen Oliveira-Abreu; José Cipolla-Neto; Jose Henrique Leal-Cardoso
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

Review 10.  Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy.

Authors:  Maria Grazia Rossino; Massimo Dal Monte; Giovanni Casini
Journal:  Front Neurosci       Date:  2019-11-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.